(Boursier.com) – Eurofins Scientific stumbles 4.5% to 94.4 euros at the end of the morning while Jefferies degraded the file to ‘keep’ despite an objective raised from 92 to 100 euros. A decline which brings the liabilities of the title since January 1 to more than 11%. The broker explains his choice by the fact that the title has reached its target price. The rise in the share was fueled by demand for Covid-19 tests, but the group’s main markets “should remain dynamic,” the broker said. The analyst believes that the 5% organic growth target “looks very comfortable” in 2022 due to strong structural demands and “very dynamic markets” for biopharmaceuticals. He expects ‘Covid-19 revenues’ of 450 million euros in 2022 and 50 ME in 2023 (1.3 billion euros expected for the 2021 fiscal year).
© 2022 Boursier.com